Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Inhibrx has raised $75.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in March 2026.
Inhibrx's investors include RA Capital Management, Lilly Asia Ventures, TCG Crossover, Perceptive Advisors, Oxford Finance LLC.
Inhibrx is headquartered in La Jolla, United States.
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Inhibrx is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Inhibrx — Funding & Investors." VCBacked, March 18, 2026, https://www.vcbacked.co/company/inhibrx. Accessed November 13, 2026.
VCBacked. (2026). Inhibrx — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/inhibrx
{{cite web |title=Inhibrx — Funding & Investors |url=https://www.vcbacked.co/company/inhibrx |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Inhibrx? Request a listing update